Haema 2016; 7(2): 242-249
by Georgia Avgerinou, Evgenios Goussetis
Stem Cell Transplant Unit, Aghia Sophia Children’s Hospital, Athens, Greece
Allogeneic hematopoietic stem cell transplantation (HsCT) has long been applied as the only potential treatment of life-threatening non malignant diseases. For patients without a matched sibling donors, a suitable alternative donor is (1) matched unrelated donor, (2) unrelated cord blood unit and (3) HLA-mismatched family donor. This article reviews the current status of HsCT in some of the more common bone marrow failure syndromes, with emphasis in acquired aplastic anemia and Fanconi anemia as well as in hemoglobinopathies and severe combined immunodeficiencies (sCID).